Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines.

摘要: The objective of this study was to compare recommendations the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines treating bipolar disorder. We reviewed a total five global treatment and compared recommendation KMAP-BP those guidelines. For initial mania, there were no significant differences across All recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy combination an MS AAP as first-line strategy mania. However, did not prefer psychotic Quetiapine, olanzapine aripiprazole AAPs nearly all phases disorder Most advocated newer options while lamotrigine depressive maintenance phases. Lithium valproic acid commonly used MSs in As research evidence accumulated over time, (such asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone once monthly) became prominent. similar guidelines, reflecting current changes prescription patterns based on data. Strong preference therapy characteristic 2018, predominantly mania severe depression. Further studies needed address several issues identified our review.